ECVT — Ecovyst Inc. · 2026-09-05 · Verdict: WATCH · Conviction 2
Price $10.21 (screen close 2026-09-04, universe_under2b.csv; no live prices available) · Mkt cap $1,117.7M (109,468,398 shares) · EV $1,527.0M · EV/EBITDA 7.6x guided FY26 · EV/adj EBIT ~12.8x · FCF yield 4.5% guided · Net debt $409.3M · ADV $13.2M Sources: 10-K 2026-02-27 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-04-15, 8-Ks 2026-05-04/05-05/06-30/08-05/08-24, Form 4s (12m). No transcript in the bundle; quotes are from earnings release prepared statements.
1. What the business actually does
Ecovyst takes spent sulfuric acid from North American refineries, regenerates it, and returns fresh acid for use as the catalyst in alkylation units; it also makes virgin sulfuric acid for mining, water treatment and industry. Regeneration and treatment were 49.9% of 2025 sales, from nine plants on the Gulf Coast and in California, with claimed number one or two share in over 95% of sales (10-K 2025, Item 1). Two events reshaped it: the December 31, 2025 sale of the Advanced Materials & Catalysts segment and the Zeolyst JVs to Technip Energies for $556.0 million, $465.0 million of it used to repay term debt; and the June 30, 2026 purchase of Calabrian's sulfur dioxide business from INEOS for $190 million, funded with a $100 million incremental term loan (10-K 2025, Item 1; 10-Q, MD&A).
2. Why it is mispriced — the edge case
The screening artifact is real. Trailing 2025 GAAP shows a $71.1 million net loss (10-K 2025, Item 7), producing our screen's 23.5x EV/EBIT, but that loss is almost entirely the $77.4 million discontinued-operations charge on the segment that was sold. Guided 2026 Adjusted EBITDA of $195-207 million against a $1,527 million EV is 7.4x to 7.8x (8-K 2026-08-05).
But an artifact is not a mispricing unless someone is forced to act on it, and I cannot find that seller. The register is institutional and value-aware: BlackRock 9.85%, Rubric Capital 9.50%, Hotchkis and Wiley 8.09% (DEF 14A 2026), on $13.2 million of daily volume, with quarterly guidance. The 25% fall from the $13.33 a director sold at on June 2 (Form 4, 2026-06-03) has support in the numbers.
3. Unit economics and growth
Q2 showed 42% sales growth to $250.0 million and 27% Adjusted EBITDA growth to $53.1 million. But about $55 million of the $73.9 million sales increase was higher sulfur costs, which the company says pass through with no net impact on gross profit, and guided 2026 sales assume roughly $220 million of such pass-through (10-Q; 8-K 2026-08-05, fn 1). Underneath, organic Adjusted EBITDA has not grown: $177.2 million in 2023, $172.7 million in 2024, $172.0 million in 2025 (10-K 2025, Item 7). The 2026 step-up is bought, via the Waggaman acid assets and Calabrian.
Worse, the guide implies the core shrinks in H2. H1 Adjusted EBITDA was $92.9 million, so the guide leaves $102-114 million for H2, of which $10-12 million is Calabrian. Core H2 is $92-102 million against $108.8 million in H2 2025 ($172.0 million less H1 $63.2 million): down 6% to 15% across the entire guided range. Management expects lower virgin acid sales in Q3 and Q4 and is "cautious about the potential for softer demand in some industrial applications" (8-K 2026-08-05).
Capital intensity is the other constraint. Guided capex of $85-95 million against D&A of $80-84 million holds guided Adjusted Free Cash Flow to $45-55 million, a 4.5% equity yield (8-K 2026-08-05). Top ten customers were 61% of 2025 sales, one customer 12% (10-K 2025, Item 1A).
4. Balance sheet and capital allocation
Debt is $497.1 million, one term loan at SOFR plus 2.00% maturing June 2031, against cash of $87.8 million (10-Q). Net debt of $409.3 million is 2.0x leverage, up from 1.2x at year end because the Calabrian loan carries no trailing EBITDA (8-K 2026-08-05). The buyback is the best part: H1 repurchases of 3,226,461 shares at an average $11.07 took shares from 111.8 million to 109.5 million, with $146.5 million left, 13% of the cap (10-Q), though whether it continues at 2.0x leverage is open. Alignment is weak: zero insider open-market purchases in twelve months against one sale (Form 4 summary).
5. Management: said versus did
The 2025 incentive plan set an Adjusted EBITDA target of $184.0 million; actual was $171.8 million, an 83.3% payout, so management missed its own plan (DEF 14A 2026, EIP table). The 2023 performance stock units were forfeited in full because the absolute TSR threshold of $10.45 was not met, the stock closing 2025 at $9.73; at $10.21 it is still near the level that paid zero. On August 21 the board replaced Michael Feehan, CFO since August 2021, the 8-K stating the separation "is considered a termination without cause" (8-K 2026-08-24). Three weeks after a raised guide, that is a firing, and no reason is given.
6. Valuation
Base: 2027 Adjusted EBITDA $210 million (2026 midpoint plus a full year of Calabrian, no synergies, no organic growth) at 7.5x, net debt $400 million, about $10.70. Bear: virgin acid weakness persists and a regeneration contract lapses, $180 million at 6.5x, about $6.95. Bull: Calabrian delivers $24 million annualized plus $10 million synergies, core holds, $235 million at 8.5x, about $13.00. Weighted 50/25/25 that is $10.34, 1% above the price. Reverse DCF: the $1,118 million equity value against guided Adjusted Free Cash Flow of $45-55 million requires, at a 9% cost of equity, about 4.3% perpetual growth, from a business whose Adjusted EBITDA has not grown in three years.
7. Catalysts and timeline
Q3 results in early November, the first quarter consolidating Calabrian and the first under a new CFO, test whether the guided core H2 decline is real. Full-year 2027 guidance in February is the first clean look at the combined company and the first sizing of synergies. About 40% of volume sits under contracts expiring at end-2026 or beyond (10-K 2025, Item 1A).
8. Risks and pre-registered kill criteria
- H2 2026 Adjusted EBITDA excluding the disclosed Calabrian contribution below $92 million, worse than the bottom of the guide.
- Net debt leverage above 2.5x at any quarter end, or zero repurchases for two consecutive quarters.
- Loss or non-renewal of the 12%-of-sales customer, or any disclosed non-renewal of a multi-year regeneration contract.
- 2027 guided Adjusted Free Cash Flow below $70 million despite a full year of Calabrian. Confirming instead: synergies quantified and Q3 core Adjusted EBITDA flat or up year over year.
9. Verdict and summary
WATCH, conviction 2. The screen's 23.5x EV/EBIT is a genuine post-divestiture artifact, since 2025 GAAP carries a $71.1 million net loss that is almost all the sold Advanced Materials business, and on the continuing base Ecovyst trades at about 7.6x guided 2026 Adjusted EBITDA for sulfuric acid regeneration plants with number one or two share and 90% of sales under pass-through contracts. But there is no forced seller to exploit, and the numbers explain the fall. Adjusted EBITDA has been flat at $177 million, $173 million and $172 million for three years and the 2026 step-up is bought with acquisitions; strip the roughly $220 million of sulfur pass-through and most of the 42% sales growth disappears; and the raised guide itself implies core H2 EBITDA down 6% to 15% year over year once Calabrian is removed. Capex of $85-95 million against D&A of $80-84 million holds free cash flow to $45-55 million, a 4.5% yield, and the price already implies about 4% perpetual growth, so probability-weighted value of $10.34 sits 1% above it. Management missed its own 2025 EBITDA plan by 7%, no insider has bought in twelve months, and the five-year CFO was terminated without cause three weeks after the raised guide. The remaining buyback, 13% of the cap, and the unsized synergies are the case for owning it, both checkable at the November print.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.